WBR0074

Revision as of 10:00, 29 July 2013 by Gerald Chi (talk | contribs) (Created page with "{{WBRQuestion |ExamType=USMLE Step 1 |MainCategory=Biochemistry, Microbiology, Pharmacology |SubCategory=Hematology, Infectious Disease |MainCategory=Biochemistry, Microbiolog...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
 
Author PageAuthor::
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Biochemistry, MainCategory::Microbiology, MainCategory::Pharmacology
Sub Category SubCategory::Hematology, SubCategory::Infectious Disease
Prompt [[Prompt::A 32-year-old homosexual intravenous drug user is admitted with a worsening respiratory distress accompanied by fever and nonproductive cough. Arterial blood gas values are pH 7.52, PaCO2 28 mm Hg, HCO3 22 mEq/L, and PaO2 70 mm Hg when breathing room air. His CD4+ count is 150 cells per microliter. Chest X-ray reveals bilateral perihilar interstitial infiltrates suggesting an infection etiology. The causative organism is detected in bronchoalveolar lavage with silver stain. Two days after therapy, he starts to have dizziness, headache, coldness in hands and feet, pale skin, and chest pain. Peripheral blood smear shows irregularly fragmented erythrocytes. Supravital stain of the smear shows immature red cells with dark blue dots and curved linear structures in the cytoplasm. Which of the following medications is most likely to be the cause of his symptoms?]]
Answer A AnswerA::Atovaquone
Answer A Explanation [[AnswerAExp::A. Atovaquone is incorrect

For mild-to-moderate PCP, alternative therapeutic regimens include: dapsone plus TMP, primaquine plus clindamycin, and atovaquone. However, atovaquone generally does not cause hemolytic anemia.]]

Answer B AnswerB::Clindamycin
Answer B Explanation [[AnswerBExp::B. Clindamycin is incorrect

For mild-to-moderate disease, alternative therapeutic regimens include: dapsone plus TMP, primaquine plus clindamycin, and atovaquone. However, clindamycin generally does not cause hemolytic anemia.]]

Answer C AnswerC::Methylprednisolone
Answer C Explanation [[AnswerCExp::C. Methylprednisolone is incorrect

Patients with moderate-to-severe disease should receive adjunctive corticosteroids as early as possible and certainly within 72 hours after starting specific PCP therapy. However, methylprednisolone generally does not cause hemolytic anemia.]]

Answer D AnswerD::Pentamidine
Answer D Explanation [[AnswerDExp::D. Pentamidine is incorrect

For moderate-to-severe disease, clindamycin-primaquine or pentamidine can be used. However, pentamidine generally does not cause hemolytic anemia.]]

Answer E AnswerE::Primaquine
Answer E Explanation [[AnswerEExp::E. Primaquine is correct

For mild-to-moderate disease, alternative therapeutic regimens include: dapsone plus TMP, primaquine plus clindamycin, and atovaquone. Common triggers of hemolytic anemia include sulfonamides and other drugs such as chloroquine, isoniazid, nalidixic acid, nitrofurantoin, and primaquine.]]

Right Answer RightAnswer::E
Explanation [[Explanation::Pneumocystis pneumonia (PCP) is an opportunistic infection caused by Pneumocystis jirovecii. The risk of PCP increases when CD4+ cell levels are less than 200 cells/μl. Symptoms include fever, non-productive cough, shortness of breath, weight loss, and night sweats. Chest films typically show diffuse, symmetrical, perihilar interstitial infiltration that may progress to a homogenous, ground-glass opacification of lung fields.

Hypoxemia, the most characteristic laboratory abnormality, can range from mild (room air arterial oxygen ≥70 mm Hg or alveolar-arterial O2 difference <35 mm Hg) to moderate (A-a DO2 ≥35 and <45 mm Hg) to severe (A-a DO2 ≥45 mm Hg).

TMP-SMX is the treatment of choice for PCP. For mild-to-moderate disease, alternative therapeutic regimens include: dapsone plus TMP, primaquine plus clindamycin, and atovaquone. For moderate-to-severe disease, clindamycin-primaquine or pentamidine can be used. Patients with moderate-to-severe disease should receive adjunctive corticosteroids as early as possible and certainly within 72 hours after starting specific PCP therapy.

His hospital course is complicated by hemolytic anemia due to increased oxidative stress, which typically occurs in patients with glucose-6-phosphate dehydrogenase deficiency. Heinz bodies, bite cells, spherocytes, and reticulocytes may be evident on peripheral blood smear.
Educational Objective:
References: ]]

Approved Approved::No
Keyword
Linked Question Linked::
Order in Linked Questions LinkedOrder::